This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
AmerisourceBergen Corporation (ABC) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.
Hunting for Growth Mixed with Value: Buy These 3 Stocks Now
by Benjamin Rains
Looking at three highly-ranked Zacks stocks that have outperformed the market over the last several years, while posting solid growth. All three stocks we dig into also offer investors great value at the moment.
Will AmerisourceBergen (ABC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter 2023 results are likely to highlight sustained stability across its Clear Aligner business.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.
AmerisourceBergen (ABC) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AmerisourceBergen (ABC) could produce exceptional returns because of its solid growth attributes.
Is AmerisourceBergen (ABC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AmerisourceBergen (ABC) and Hologic (HOLX) have performed compared to their sector so far this year.
Is AmerisourceBergen (ABC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's How Much a $1000 Investment in AmerisourceBergen Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Beat the Market Like Zacks: Shopify, Medtronic, Oracle in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Beat the Market Like Zacks: NVIDIA, VirTra, Rockwell Medical in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Why Is Henry Schein (HSIC) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is AmerisourceBergen (ABC) Up 2% Since Last Earnings Report?
by Zacks Equity Research
AmerisourceBergen (ABC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen
by Zacks Equity Research
J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen are part of the Zacks Screen of the Week article.
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.